Abstract

Background: Progressive multifocal leukoencephalopathy is a fatal demyelinating condition due to reactivation of latent JC virus in cerebral white matter. Its prevalence is 1in 200,000 and extremely rare in immunocompetent individuals. It can mimic subacute stroke, brain tumours and other demyelinating conditions which have different outcomes. PML typically occurs in an immunocompromised patient, where the archetype JC virus gains pathogenic potential and initiate oligodendroglial inflammation. Currently, the immune reconstitution is considered as the treatment of choice; however, paradoxical worsening with IRIS PML is a significant challenge. There is limited evidence available on how to manage PML in immune competent patients. Direct antiviral agents have no convincing evidence to-date. There is anecdotal evidence that IL-2, filgrastim, and vaccination may be helpful. Case presentation: A 74-year-old man presented with right-sided weakness and dysphasia. He was initially managed as having subacute stroke based on imaging and clinical findings. He subsequently deteriorated, triggering to revisit of the original diagnosis and repeat imaging. He underwent extensive workup, including lumbar puncture and JC viral testing. He was commenced on Mirtazapine to prevent JC viral spread; however, he later passed away. A subsequent post-mortem brain biopsy confirmed the progressive leukoencephalopathy. Conclusion: Even though extremely rare, progressive multifocal leukoencephalopathy should be considered in the differential diagnosis of progressive neurological conditions. It is essential to rule out other treatable conditions as progressive multifocal leukoencephalopathy has a fatal outcome invariably.

Highlights

  • Progressive Multifocal Leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system due to reactivation of polyomavirus called John Cunningham (JCV) virus [1]

  • Typical clinical findings of PML are similar to a stroke, but PML is usually progressive and fatal

  • JCV is prevalent in 50-90% of healthy adults, and around 85%of the population has antibodies to the JC virus

Read more

Summary

Introduction

Progressive Multifocal Leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system due to reactivation of polyomavirus called John Cunningham (JCV) virus [1]. Even though PML was described early as 1952 by Ästro m and colleagues, the actual causative agent was identified as the JCV in a Hodgkin disease patient’s brain in 1972 [2]. Typical clinical findings of PML are similar to a stroke, but PML is usually progressive and fatal. PML occurs in an immunocompetent patient is extremely rare [3]

Case Presentation
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.